Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
Document Type
Article
Publication Date
4-8-2025
Publication Title
Oncogene
Abstract
Breast cancer is the second largest cancer in the world, and it has highest mortality rate in women worldwide. The aberrant activation of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway plays an important role in uncontrolled breast cancer cell proliferation. Therefore, targeting CDK4/6 to improve overall survival rates has been a strong interest in breast cancer therapeutics. Till date, four CDK4/6 inhibitors have been developed and approved for hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer therapies with great success. However, acquired resistance to CDK4/6 inhibitors has emerged and limits their effectiveness in breast cancer. In this review, we systematically discussed the mechanisms of resistance to CDK4/6 inhibitors including the cell cycle-specific and cell cycle-nonspecific mechanisms. Also, we analyzed combination strategies with other signaling inhibitors in clinical and preclinical settings that further expand the clinical application of CDK4/6 inhibitors in future breast cancer therapies.
First Page
1135
Last Page
1152
PubMed ID
40200094
Volume
44
Issue
17
Recommended Citation
Guo, Zhengfei; Dong, Richard W.; Wu, Yusheng; Dong, Shengli; and Alahari, Suresh K., "Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment" (2025). School of Medicine Faculty Publications. 3691.
https://digitalscholar.lsuhsc.edu/som_facpubs/3691
10.1038/s41388-025-03378-0